Anthem Biosciences Limited
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 17.5%
Concerns1
- Negative free cash flow (βΉ159 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 7 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.84 K Cr | β | βΉ506.00 Cr | β | β | 20.5% | 29.8% | 34.9% |
| Mar 2024 | βΉ1.42 K Cr | β | βΉ375.00 Cr | β | β | 19.4% | 34.2% | -2.8% |
| Mar 2023 | βΉ1.06 K Cr | β | βΉ386.00 Cr | β | β | 22.2% | -14.1% | -4.9% |
| Mar 2022 | βΉ1.23 K Cr | β | βΉ406.00 Cr | β | β | 29.9% | 11.6% | 49.8% |
| Mar 2021 | βΉ1.10 K Cr | β | βΉ271.00 Cr | β | β | 38.7% | 74.2% | 191.4% |
| Mar 2020 | βΉ633.00 Cr | β | βΉ93.00 Cr | β | β | 22.1% | 1.1% | 20.8% |
| Mar 2019 | βΉ626.00 Cr | β | βΉ77.00 Cr | β | β | 23.3% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2025 |
|---|---|
| Revenue / Net Sales | 1,841 |
| Total Expenses | 1,151 |
| EBIT / Operating Profit | 690 |
| OPM % | 37% |
| Other Income | 109 |
| Finance Costs | 9 |
| Depreciation & Amortisation | 78 |
| Profit Before Tax | 711 |
| Tax % | 29% |
| Net Profit / PAT | 506 |
| EPS (βΉ) | 9.05 |
| Dividend Payout % | 0% |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Anthem Biosciences Limitedthis co. | βΉ35.38 K Cr | βΉ1.84 K Cr | 66.20 | 12.40 | 61.40 | 29.8% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |